GoldenGolden
Adicet Bio

Adicet Bio

Adicet Bio is a biotechnology company creating immune cell therapies for treating cancer and other diseases.

Adicet Bio is a biotechnology company creating immune cell therapies for treating cancer and other diseases that is headquartered in Menlo park, California and was founded in 2014 by Aya Jakobovitis.

Funding
Venture

On August 26, 2015 Adicet Bio completed a venture capital round raising $14.6 million in funding from undisclosed investors.

Series A

On January 27, 2016 Adicet Bio completed their series A funding round with $51 million in funding from OrbiMed (lead investor), Pontifax, and Novartis Venture Fund.

Acquisitions
Applied Immune Technologies

On January 27, 2016 Adicet Bio acquired the Israeli immunotherapy company Applied Immune Technologies.

Timeline

October 2019
Adicet Bio raises a $80,000,000 series B round from Consensus Business Group, DSC Investments, Handok, Johnson & Johnson Innovation, Johnson & Johnson Innovation – JJDC, KB Investment, Novartis Venture Fund, OCI Enterprises, OrbiMed, Pontifax Venture Capital, Regeneron Pharmaceuticals, SBI Japan-Israel Innovation Fund, Samsung Venture Investment Corporation, Samsung Ventures and aMoon Fund.
January 27, 2016
Series A funding round

On January 27, 2016 Adicet Bio completed their series A funding round with $51 million in funding from OrbiMed (lead investor), Pontifax, and Novartis Venture Fund.

August 26, 2015
Venture funding round

On August 26, 2015 Adicet Bio completed a venture capital round raising $14.6 million in funding from undisclosed investors.

2014
Adicet Bio was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Adicet Bio funding round, October 2019
80,000,000
October 2019
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 13, 2021
BioSpace
Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced the appointment of Blake Aftab, Ph.D., as Vice President of Research.
Research and Markets
January 25, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Cellular Immunotherapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.